InsidersTradesSigma
Pharma Mar, S.A.: insider trades · Spain · CNMV
CNMV:pharma-mar-saES0169501022ES·CNMVMcap 1.7Bn€Healthcare & Pharma
Discover the full directors' dealings record of Pharma Mar, S.A., a listed equity based in Spain. Shares are quoted on ES ES, under the authority of CNMV. Operating in the Healthcare & Pharma sector, Pharma Mar, S.A. has recorded 57 public disclosures. Market capitalisation: €1.7bn. The latest transaction was filed on 22 April 2026 — Purchase. Among the most active insiders: MONTSERRAT ANDRADE DETRELL. Every trade is openly available.
57
Insider Decl.
0
Thresholds
€2m
50 ops.
Buy Volume
€6,600
1 ops.
Sell Volume
Financial data
96.30 €
Analyst consensus
9 analystsBuy
75.00 €Target 108.89 €(+13%)125.00 €
Valuation
PER (trailing)20.9x
PER (forward)13.0x
P/Book6.6x
Beta0.37
Balance sheet & cash
Market cap1.67 Bn€
Debt / Equity19%
Profitability & ownership
ROE36.0%
ROA11.2%
% insiders29.7%
% institutions6.6%
Last declaration on 22 April 2026
Declarations57 total
Executives●Purchase29CNMV
€9,345100 shares@ €93.450.0006% mcap100.0% of flow
ShareXMAD
CNMV:2026055309·
Ideal exit: 16 Jan 2027 (T+270)
Executives●Other26CNMV
€9,952122 shares@ €81.570.0006% mcap100.0% of flow
ShareXOFF
CNMV:2026048741·
Executives●Other26CNMV
€9,952122 shares@ €81.570.0006% mcap100.0% of flow
ShareXOFF
CNMV:2026048744·
Executives●Purchase26CNMV
€11,909146 shares@ €81.570.0007% mcap100.0% of flow
ShareXMAD
CNMV:2026046976·
Ideal exit: 21 Dec 2026 (T+270)
Executives●Purchase16CNMV
€8,100100 shares@ €81.000.0005% mcap16.3% of flow
ShareXMAD
CNMV:2026042671·
Ideal exit: 18 Dec 2026 (T+270)
Executives●Sale15CNMV
€6,60075 shares@ €88.000.0004% mcap13.3% of flow
ShareXMAD
CNMV:2026040871·
Executives●Purchase15CNMV
€6,07575 shares@ €81.000.0004% mcap12.2% of flow
ShareXMAD
CNMV:2026038713·
Ideal exit: 7 Dec 2026 (T+270)
Executives●Purchase15CNMV
€5,06170 shares@ €72.300.0003% mcap10.2% of flow
ShareXMAD
CNMV:2025138818·
Ideal exit: 3 Aug 2026 (T+270)
Executives●Purchase16CNMV
€7,635100 shares@ €76.350.0005% mcap15.0% of flow
ShareXMAD
CNMV:2025132590·
Ideal exit: 20 Jul 2026 (T+270)
Executives●Purchase21CNMV
€37,285500 shares@ €74.570.0022% mcap69.5% of flow
ShareXMAD
CNMV:2025130674·
Ideal exit: 21 Jul 2026 (T+270)
Executives●Purchase18CNMV
€18,920215 shares@ €88.000.0011% mcap38.1% of flow
ShareXMAD
CNMV:2025124295·
Ideal exit: 4 Jul 2026 (T+270)
Executives●Purchase15CNMV
€4,96062 shares@ €80.000.0003% mcap10.0% of flow
ShareXMAD
CNMV:2025118883·
Ideal exit: 27 Dec 2025 (T+270)
Executives●Purchase16CNMV
€7,865100 shares@ €78.650.0005% mcap15.5% of flow
ShareXMAD
CNMV:2025084231·
Ideal exit: 5 Oct 2025 (T+270)
Executives●Purchase16CNMV
€8,381100 shares@ €83.810.0005% mcap15.6% of flow
ShareXMAD
CNMV:2025078458·
Ideal exit: 3 Mar 2026 (T+270)
Executives●Purchase16CNMV
€8,310100 shares@ €83.100.0005% mcap16.4% of flow
ShareXMAD
CNMV:2025078461·
Ideal exit: 3 Mar 2026 (T+270)
Executives●Purchase16CNMV
€8,760100 shares@ €87.600.0005% mcap17.3% of flow
ShareXMAD
CNMV:2025077199·
Ideal exit: 27 Feb 2026 (T+270)
Executives●Purchase15CNMV
€7,95690 shares@ €88.400.0005% mcap14.8% of flow
ShareXMAD
CNMV:2025072593·
Ideal exit: 21 Dec 2025 (T+270)
Executives●Purchase24CNMV
€199,4862,402 shares@ €83.050.012% mcap100.0% of flow
ShareXMAD
CNMV:2025072213·
Ideal exit: 14 Feb 2026 (T+270)
Executives●Purchase15CNMV
€7,420100 shares@ €74.200.0004% mcap14.6% of flow
ShareXMAD
CNMV:2025068237·
Ideal exit: 3 Feb 2026 (T+270)
Executives●Purchase15CNMV
€7,853111 shares@ €70.750.0005% mcap5.3% of flow
ShareXMAD
CNMV:2025047967·
Ideal exit: 2 Jan 2026 (T+270)
Executives●Purchase34CNMV
€99,6791,425 shares@ €69.950.0060% mcap46.4% of flow
ShareXMAD
CNMV:2025047966·
Ideal exit: 2 Jan 2026 (T+270)
Executives●Purchase15CNMV
€4,11050 shares@ €82.200.0002% mcap8.1% of flow
ShareXMAD
CNMV:2025045462·
Ideal exit: 27 Dec 2025 (T+270)
Executives●Purchase15CNMV
€4,44550 shares@ €88.900.0003% mcap8.8% of flow
ShareXMAD
CNMV:2025043092·
Ideal exit: 21 Dec 2025 (T+270)
Executives●Other14CNMV
0271,875 shares0
ShareXOFF
CNMV:2025010564·
Executives●Purchase14CNMV
€3,17040 shares@ €79.250.0002% mcap2.1% of flow
ShareXMAD
CNMV:2025001624·
Ideal exit: 6 Oct 2025 (T+270)
25 of 57 declarations
About Pharma Mar, S.A.
PHARMA MAR, S.A. is a Spanish biopharmaceutical company focused on the research and development of cancer treatments. It is listed on the Spanish stock market, XMAD.
